Liquidity is rapidly eroding, with cash reserves falling from $20.5 million in 2025Q3 to $7.5 million in 2026Q3, alongside a $100 million capital expenditure in the most recent quarter.
| Cash from Operations | -10.42M | -20.84M | -50.47M | -52.48M | -48.75M | -31.96M |
| Operating CF Margin % | - | - | -77.3% | -107.51% | -119.78% | -91.86% |
| Operating CF Growth % | 200.43% | 58.7% | 3.83% | -7.67% | -52.5% | - |
| Net Income | -60.82M | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
| Depreciation & Amortization | 0 | 368K | 383K | 386K | 326K | 285K |
| Stock-Based Compensation | 362K | -144K | 2.28M | 3.59M | 8.35M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 51.3M | -272K | 13.36M | 326K | -19.84M | -7.88M |
| Working Capital Changes | -1.26M | -4.85M | -84.28M | -24.95M | 16.88M | 16.94M |
| Change in Receivables | 0 | 0 | 85K | 9.96M | -2.46M | 15.7M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 244K | -2.99M | -3.15M | -1.78M | 1.56M | 3.92M |
| Cash from Investing | -97.33M | 35.15M | 49.14M | 53.69M | 6.89M | 24.71M |
| Capital Expenditures | -100M | 0 | -7K | -35K | -479K | -708K |
| CapEx % of Revenue | - | - | 0.01% | 0.07% | 1.18% | 2.03% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 2.67M | 10K | 0 | 0 | 0 | 0 |
| Cash from Financing | 94.82M | 0 | -11.87M | -40K | 49.05M | 3.47M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 94.61M | 0 | 0 | 0 | 52.33M | 3.47M |
| Dividends Paid | 0 | 0 | -11.66M | 0 | 0 | 0 |
| Share Repurchases | -2M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 208K | 0 | -208K | -40K | -3.27M | 0 |
| Net Change in Cash | -12.93M | 14.31M | -13.2M | 1.17M | 7.2M | -3.79M |
| Free Cash Flow | -10.42M | -20.84M | -50.48M | -52.52M | -49.23M | -32.67M |
| FCF Margin % | - | - | -77.31% | -107.59% | -120.95% | -93.9% |
| FCF Growth % | 70.77% | 58.71% | 3.88% | -6.69% | -50.66% | - |
| FCF per Share | -1.56 | -3.13 | -7.58 | -7.88 | -7.87 | -5.71 |
| FCF Conversion (FCF/Net Income) | 0.17x | 1.31x | -2.84x | 1.65x | 0.90x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Existential cash burn risk
As reported in recent financial filings, LITS exhibits a persistent disconnect between net income and operating cash flow, with the 2026Q3 net loss of $23.7 million significantly outpacing the $1.5 million cash outflow, suggesting that non-cash charges or legacy accounting adjustments are heavily distorting the firm's true economic performance.
The wide variance between net income and operating cash flow suggests that the company's reported losses are heavily influenced by non-cash items, likely related to the wind-down of legacy pharmaceutical assets. Investors should monitor whether this gap narrows as the company transitions to a simpler, albeit currently non-existent, revenue model.
Based on the provided quarterly data, LITS has maintained a negative free cash flow trajectory for the past ten quarters, with the most recent 2026Q3 period showing a $1.5 million outflow, confirming that the company is currently consuming its remaining capital reserves without generating any offsetting operational cash.
The persistent negative free cash flow indicates that the company is in a state of capital depletion rather than value creation. Without a clear path to revenue, the current trajectory suggests that the firm's survival is entirely dependent on its remaining cash balance rather than operational self-sufficiency.
According to the 2026Q3 financial data, LITS recorded a significant $100 million capital expenditure, a figure that appears anomalous given the company's zero-revenue status and suggests either a major strategic asset acquisition or a one-time accounting event that warrants further investigation by stakeholders.
This sudden spike in capital intensity is highly unusual for a firm that has otherwise reported minimal investment activity. It may indicate an attempt to acquire digital asset infrastructure, though the lack of corresponding revenue growth suggests this capital has yet to yield any productive return.
As evidenced by the $1.8 million in share repurchases during 2026Q3, LITS is actively returning capital to shareholders despite its lack of revenue, a strategy that appears counterintuitive for a firm in the midst of a high-risk pivot to a new, unproven business model.
The decision to prioritize buybacks while the core business is in a state of total transition suggests a potential lack of internal investment opportunities. This allocation strategy may be viewed as a signal that management is prioritizing short-term liquidity for investors over long-term operational reinvestment.
Based on the reported quarterly figures, LITS has experienced significant fluctuations in working capital, including a $245,000 inflow in 2026Q3, which likely reflects the liquidation of legacy pharmaceutical inventory or the settlement of outstanding liabilities rather than any underlying improvement in operational efficiency.
The erratic nature of these working capital changes is characteristic of a business undergoing a forced wind-down. Investors should be cautious, as these inflows are likely non-recurring and do not represent a sustainable source of liquidity for the company's future operations.
Quick answers to the most common questions about buying LITS stock.
Lite Strategy, Inc. (LITS) generated $-20.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Lite Strategy, Inc. (LITS) reported negative free cash flow of $20.8M in 2025, indicating capital requirements exceeded cash from operations.
Lite Strategy, Inc. (LITS) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.